Public Sector Pension Investment Board grew its position in Elevance Health, Inc. (NYSE:ELV - Free Report) by 275.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 222,996 shares of the company's stock after buying an additional 163,585 shares during the quarter. Public Sector Pension Investment Board owned approximately 0.10% of Elevance Health worth $95,147,000 at the end of the most recent quarter.
Several other institutional investors have also made changes to their positions in the company. Rothschild Investment LLC raised its holdings in shares of Elevance Health by 162.6% during the third quarter. Rothschild Investment LLC now owns 3,761 shares of the company's stock valued at $1,462,000 after acquiring an additional 2,329 shares during the period. Sompo Asset Management Co. Ltd. boosted its stake in Elevance Health by 29.3% in the 3rd quarter. Sompo Asset Management Co. Ltd. now owns 1,616 shares of the company's stock worth $628,000 after purchasing an additional 366 shares during the period. Ironwood Investment Counsel LLC grew its position in Elevance Health by 1.9% during the 3rd quarter. Ironwood Investment Counsel LLC now owns 12,620 shares of the company's stock worth $4,907,000 after purchasing an additional 234 shares in the last quarter. Edgestream Partners L.P. purchased a new position in Elevance Health during the 3rd quarter worth approximately $609,000. Finally, Banco Santander S.A. raised its stake in Elevance Health by 26.0% during the 3rd quarter. Banco Santander S.A. now owns 13,663 shares of the company's stock valued at $5,312,000 after purchasing an additional 2,818 shares during the period. 89.24% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Elevance Health news, EVP Ratnakar Lavu sold 1,300 shares of the business's stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $440.00, for a total value of $572,000.00. Following the transaction, the executive vice president owned 14,849 shares in the company, valued at $6,533,560. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Mark Kaye sold 10,584 shares of the company's stock in a transaction dated Thursday, October 22nd. The stock was sold at an average price of $440.13, for a total value of $4,658,335.92. Following the completion of the transaction, the chief financial officer directly owned 19,919 shares in the company, valued at approximately $8,766,949.47. The trade was a 34.70% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.34% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
ELV has been the subject of a number of research analyst reports. Royal Bank Of Canada increased their target price on Elevance Health from $424.00 to $455.00 and gave the company a "sector perform" rating in a report on Thursday, October 22nd. TD Cowen lifted their price target on Elevance Health from $465.00 to $495.00 and gave the company a "buy" rating in a report on Friday, October 23rd. Guggenheim upped their price target on Elevance Health from $460.00 to $485.00 and gave the company a "buy" rating in a research report on Thursday, October 22nd. Robert W. Baird increased their price objective on Elevance Health from $393.00 to $406.00 and gave the stock a "neutral" rating in a research note on Thursday, October 22nd. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $451.00 price objective on shares of Elevance Health in a research note on Friday, October 23rd. Fifteen investment analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat, Elevance Health presently has an average rating of "Moderate Buy" and an average price target of $456.48.
Get Our Latest Analysis on Elevance Health
Elevance Health Stock Down 2.6%
Elevance Health stock opened at $434.47 on Wednesday. Elevance Health, Inc. has a twelve month low of $274.84 and a twelve month high of $450.69. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.47 and a current ratio of 1.47. The firm has a market cap of $93.87 billion, a PE ratio of 18.53, a P/E/G ratio of 2.13 and a beta of 0.63. The firm's 50 day moving average price is $416.83 and its two-hundred day moving average price is $376.16.
Elevance Health (NYSE:ELV - Get Free Report) last issued its earnings results on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.71 by $2.28. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. The company had revenue of $50.44 billion during the quarter, compared to analyst estimates of $49.28 billion. During the same quarter last year, the business posted $6.03 EPS. The company's revenue for the quarter was up .7% on a year-over-year basis. On average, research analysts predict that Elevance Health, Inc. will post 29.15 EPS for the current fiscal year.
Elevance Health Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be given a dividend of $1.72 per share. The ex-dividend date of this dividend is Friday, December 4th. This represents a $6.88 dividend on an annualized basis and a yield of 1.6%. Elevance Health's dividend payout ratio (DPR) is presently 29.34%.
Elevance Health Company Profile
(
Free Report)
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Featured Articles
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Elevance Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elevance Health wasn't on the list.
While Elevance Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.